ACALABRUTINIB
Information current as at: 1 June 2026
PBAC meeting date: July 2026
Submission Details
- Brand name:
-
- Calquence®
- Form and strength:
-
- Tablet 100 mg
- Submission sponsor:
- ASTRAZENECA PTY LTD
- Condition/indication:
(therapeutic use) -
- Mantle cell lymphoma (MCL)
- Listing requested:
- To consider the sponsor's revised proposal for listing acalabrutinib for use in combination with bendamustine and rituximab for the first-line treatment of adult patients with Stage III or IV MCL who are ineligible for stem cell transplantation. This item was previously recommended by the PBAC at its July 2025 meeting.
- Funding program:
- PBS General Schedule
- Request authority level:
- Authority Required (Telephone/Online)
- PBAC Submission type:
- Change to existing listing (–)
- Comment:
- --
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - July 2026 PBAC meeting
-
Opportunity for consumer comment: - Open 25/03/2026 and close 20/05/2026 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Pending PBAC outcome (see PBAC Outcomes)
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID
1202
Page last updated
31 May 2026
v.9.19